Studies include Alpha, Beta, Gamma, Delta, Epsilon and Iota and it maintains antibodies for six months after the second dose
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
EPS at Rs 32.19
Substantial reduction in losses
Targeting KIT by frameshifting mRNA transcripts as a therapeutic strategy for aggressive mast cell neoplasm
It’s an AB-rated generic therapeutic version of Durezol
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
The company is eligible for 12 months exclusivity from launch
The sales of vaccines have registered a growth of 41% in Q1 FY22, and the sale of health products have registered a growth of 94% in Q1 FY22.
The aim is to create new genomics solutions that could combat cancer and advance market access
Subscribe To Our Newsletter & Stay Updated
